Stock comparison
Gilead Sciences
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GILD
Gilead Sciences
Market cap
$166.82B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GILD | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 60C | 77B | LMAT |
| Benjamin Graham | 73B | 89A | LMAT |
| Philip Fisher | 61C | 81C | LMAT |
| Peter Lynch | 55C | 67B | LMAT |
| Joel Greenblatt | 47D | 56D | LMAT |
| Charlie Munger | 74C | 68D | GILD |
| Terry Smith | 71B | 69D | GILD |
Side-by-side metrics
| Metric | GILD | LMAT |
|---|---|---|
| Market cap | $166.82B | $2.23B |
| P/E (TTM) | 17.5x | 37.1x |
| EV/EBIT | 15.0x | 36.6x |
| ROIC (TTM) | 20.31% | 9.43% |
| Gross margin | 79.35% | 72.39% |
| Net margin | 30.99% | 24.35% |
| Revenue CAGR 5y | 1.9% | 12.75% |
| EPS CAGR 5y | 8.37% | 19.04% |
| Debt / Equity | 0.9x | 0.5x |
| Dividend yield | 2.46% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GILD leads on
- Market cap$166.82Bvs $2.23B+99%
- Dividend yield2.46%vs 0.84%+66%
- EV/EBIT15.0xvs 36.6x+59%
- ROIC (TTM)20.31%vs 9.43%+54%
LMAT leads on
- Revenue CAGR 5y12.75%vs 1.9%+85%
- EPS CAGR 5y19.04%vs 8.37%+56%
- Debt / Equity0.5xvs 0.9x+50%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.